Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects With Existing Hypertension Requiring Antihypertensive Therapy

Next Previous
Trial Profile

A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects With Existing Hypertension Requiring Antihypertensive Therapy

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 27 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Celecoxib (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Kitov Pharmaceuticals; Purple Biotech

Most Recent Events

  • 26 Oct 2017 According to a Kitov Pharmaceuticals media release, primary endpoint has been met. (Mean reduction in average daytime (9:00 to 21:00) ambulatory systolic blood pressure (SBPday))
  • 26 Oct 2017 Results published in a Kitov Pharmaceuticals Media Release.
  • 31 Jul 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top